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ess: ozge.yilmaz@bayarSummary Gastroesophageal reflux disease (GERD) is commonly associated with
asthma; however, frequency in nonatopic children with asthmatic symptoms is
unknown. The aim of this study was to determine the frequency of gastroesophageal
reflux (GER) in nonatopic children with asthma-like airway disease that recur despite
conventional asthma treatment and to evaluate the clinical response to lansoprazole
treatment. Twent-five nonatopic children aged between 1 and 16 years who have
asthma-like airway disease and 25 healthy children were included in the study. All
cases underwent 24 h pH monitoring with dual sensor catheters. Additionally, acid
suppressor treatment was administered to patients diagnosed as having GERD and
clinical response was evaluated.
Major symptoms encountered in the patient group included wheezing and cough
(88%, and 32%, respectively). Reflux episodes were more common in distal esophagus
during the prone position (reflux index (RI) of 11.5710.3 vs. 16.279.4 during supine
vs. prone). All distal esophageal parameters were significantly higher in the patient
group except number of reflux episodes lasting longer than 5min (RI of 13.3713.1
vs. 3.972.9 in the patient vs. control groups, respectively). There was a significant
improvement in symptoms and requirement for medication with treatment (number
of systems decreased from 2.370.6 to 0.470.6, P ¼ 0:00).
In conclusion, GERD is significantly more common in nonatopic children with
asthma-like airway disease compared to the controls and clinical improvement is
significant after acid suppressor treatment. Thus, we suggest that children followed-
up with the diagnosis of nonatopic asthma with recurrent exacerbations despite
adequate asthma treatment have a high frequency of GER and that lansoprazole
treatment may be considered early in management.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
5222950; fax: +90 232 4899623.
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Prevalence of asthma symptoms in children reaches
up to 30% in some populations.1 The pathophysiol-
ogy of this disease depends on airway hyperrespon-
siveness and airflow limitation.2 Only around 10% of
asthmatic children have been reported to be
nonatopic.3 Allergen exposure is an important
factor in exacerbations of respiratory symptoms in
children with atopic asthma. However, other
factors like gastroesophageal reflux disease (GERD)
may be contributing to asthmatic exacerbations in
nonatopics because this factor is absent. GERD,
which is the passive regurgitation of gastric con-
tents retrograde into the esophagus may be
associated with asthma.4–6 However, exact causal
relationship has not been confirmed between
asthma and GERD.4 Most suitable diagnostic tool
for GERD is 24 h pH monitoring with a sensitivity
and specificity above 90%.5,7,8 The relationship
between asthma and GERD has been detected in
many studies by 24 h pH monitoring.7,9–11 However,
these studies have not been conducted on a specific
subgroup of asthmatic patients and a more precise
relationship can be detected if the study popula-
tion is limited to specific subgroups.
Many different categories of drugs like H2
receptor antagonists, antacids, prokinetics, and
proton pump inhibitors (PPIs) may be used in the
treatment of GERD.12,13 Among these, PPIs consti-
tute the most effective treatment option for
GERD.13–16 It has been reported that lansoprazole
produce greater symptom relief than omepra-
zole.17 Thus, lansoprazole therapy was given to
nonatopic children with asthma-like airway disease
and GERD in our study.
Therefore, the aim of this study was to detect
the frequency of GERD in a subgroup of nonatopic
children who have asthma-like airway disease that
recur despite asthma treatment and also to
evaluate the influence of lansoprazole treatment
on asthma severity.Material and methods
Study population
Twenty-five nonatopic children (16 boys and 9 girls)
aged between 1 and 16 years (mean7SD of
72.6738.1 months) who have asthma-like airway
disease with recurrent exacerbations despite con-
ventional asthma therapy (such as inhaled steroids,
bronchodilator, etc.) directed by international
concencus report were included in this prospectivestudy.18 It was carried out during the period
between January 2003 and October 2004.Inclusion and exclusion criteria
Diagnosis of asthma-like airway disease was based
on history of recurrent cough and wheezing with
prolonged expiration time which demonstrated
clinical reversibility with short effective broncho-
dilator therapy, b2 agonist. Absence of atopy was
confirmed by normal immunoglobulin E values in
children less than 5 years of age and negative skin
prick test in the ones above 5 years of age.
Immunoglobulin levels were normal; purified pro-
tein derivative (PPD) and sweat chloride test were
negative in all the patients. None of the children
included in the study had body mass index above 20
to avoid the GER provoking influence of obesity.Study design
All patients and control subjects underwent 24 h pH
monitoring. Patients diagnosed as having GERD
according to the results of 24 h monitoring received
acid suppressor treatment (lansoprozole). Then,
the results of this treatment were evaluated on the
basis of symptoms, requirement of bronchodilator,
systemic steroid use, days of hospitalizations and
number of acute asthmatic attacks.pH monitoring
All cases underwent 24 h ph monitoring according
to a standard protocol. None of the subjects had
received anti-reflux treatment during the last 1
month. Moreover, 1 week before the procedure all
medications which might interfere with the results
were discontinued. Then an antimony catheter
with a diameter of less than 2.1mm and two
sensors were placed nasally following an overnight
fast. The sensors of the catheter were 10 cm apart
to measure pH in the proximal and distal esopha-
gus. Position of the catheter was verified by chest
X-ray to be 2–3 cm above the diaphragm.9 Measure-
ments of pH were recorded using a pH recorder
(Digitrapper Mk 3, Synetics Medical AB, Stockholm,
Sweden). Patients received regular feeds during
recording and daily activities resumed as normal.
Parents recorded the meal times and position of the
patients using the buttons on the recorder. Re-
corded pH data were downloaded in an IBM
compatible computer and analyzed by a software
(EsopHogram Software System). Fraction of time
with pH for proximal and distal esophagus was
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than 4%, respectively.19–21
Results of the 24 h pH monitoring of an asympto-
matic group was obtained from a previous study by
Aydog˘du et al.22 Age means of the patient and
control groups were not statistically different
(72.7738.1 and 92.6743.3 months, respectively;
P ¼ 0:09). The same protocol was used for pH
recordings with the pH recorder of the same brand.
Similar to our study, an antimony catheter with two
sensors was used; however, since only distal sensor
parameters were recorded at that time, gastro-
esophageal reflux (GER) parameters of the distal
sensor of the patient group were compared to those
of this control group.22
Treatment
Patients diagnosed as having GER received treat-
ment with PPIs, namely lansoprosol at a dose of
1mg/kg/day taken 2 h before meals for 3 months.
All the children and families were informed about
conservative measures of GER control. Patients
received inhaled steroid, fluticasone propionate
125mcgr/dose by 12 h intervals, as anti-asthmatic
treatment. The ones who were hospitalized re-
ceived nebulized salbutamol and parenteral ster-
oids namely intravenous dexamethasone for
treatment of the acute exacerbations.
Evaluation of disease severity
Clinical response to treatment was evaluated by
evaluating the presence of symptoms, days of
bronchodilator, parenteral steroid and hospitaliza-
tion requirement as well as the number of asthma
exacerbations. Symptoms that were evaluated
included vomiting, wheezing, hoarseness, recur-
rent pneumonia, sore throat, chronic cough,
regurgitation and laryngitis.9,23–25 Post-treatment
evaluation was performed during the 3-month
period after initiation of GER treatment. Pre-Table 1 Distribution of gastroesophageal reflux related
diseases.
Symptom Present
n %
Vomiting 1 4
Wheezing 22 88
Recurrent LRTI 4 16
Chronic cough 23 32
LTRI, lower respiratory tract infection.treatment evaluation was performed according to
the patient records of the same months of the
previous year to avoid seasonal influence like air
pollution, and viral infections on asthma symptoms.
Statistical analysis
Statistical analyses were performed by SPSS 11.0
(Chicago IL) computer program. Paired samples t-
test, independent samples t-test and Pearson’s w2-
test was used for the statistical analysis. P values
less than 0.05 were regarded as statistically
significant.Results
Gastroesophageal reflux related pulmonary
symptoms
Symptoms encountered in the patient group in-
cluded vomiting, wheezing, recurrent lower re-
spiratory tract infection, chronic cough in 4%, 88%,
16% and 32%, respectively (Table 1).
pH monitoring
Analysis of the GER parameters in the patient group
revealed that the number of reflux episodes were
more common during prone position compared to
that during supine in both proximal (101.6755.8/
patient vs. 34.9723.2/patient, P ¼ 0:09) and
distal (208.37143.9/patient vs. 48.8744.8/pa-
tient, P ¼ 0:00) esophagus. This difference was
not statistically significant except for total num-
ber of reflux episodes in distal esophagus. However,
in the proximal esophagus, all other parameters
like number of reflux lasting longer than 5min,
reflux index (RI) and longest episode of reflux were
higher when supine (1.871.2/patient, 5.875.6/
patient, 6.277.6/patient, respectively). Contra-
rily, number of reflux episodes lasting longersymptoms among children with asthma-like airway
Absent
n % Total
24 96 25
3 13 25
21 84 25
2 8 25
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Table 2 Comparison of GER parameters of the distal esophagus between patient and control groups.
Parameter Control group Patient group P
] of reflux episodes 94.4768.1 248.97203.4 0.00
] of reflux episodes 45min 1.671.6 5.474.3 0.08
Reflux index 3.972.9 13.3713.1 0.01
Longest episode of reflux 7.074.6 18.3713.8 0.02
P value was accepted as significant less than 0.05.
Table 3 Analysis of the response to treatment in children with asthma-like airway disease according to the
symptom score, bronchodilator and steroid requirement and duration of hospitalization (Mean7SD).
Parameter Before treatment After treatment P
Number of symptoms 2.370.6 0.470.6 0.00
Bronchodilator use 8.376.8 1.473.4 0.00
Systemic steorid use (day/patient) 5.375.4 0.471.2 0.00
Asthma attack (number/patient) 1.571.1 0.370.6 0.00
Hospitalization (day/patient) 9.177.7 0.572.2 0.00
P value was accepted as significant less than 0.05.
H. Yu¨ksel et al.396than 5min and RI in distal esophagus were higher
when prone (2.672.1/patient, 16.279.4/patient,
respectively). Longest episode of reflux in distal
esophagus occurred when supine (16.179.6/
patient).
Comparison of the distal esophageal parameters
among control and patient groups revealed that
total RI, total number of reflux episodes and
longest duration of reflux were significantly higher
in the patient group; number of reflux episodes
lasting longer than 5min was also higher in the
patient group, though statistically insignificant
(Table 2).
Asthmatic medication
Symptoms, days of bronchodilator and/or steroid
requirement and number of asthma exacerbations
as well as in-hospital days per patient decreased
with acid suppressor treatment. The decrease in all
these parameters were highly significant (P ¼ 0:00)
(Table 3).Discussion
GER which is the passive regurgitation of gastric
contents retrograde into the esophagus is termed
as pathological GERD when it results in poor weight
gain, signs of esophagitis, persistent respiratorysymptoms and neurobehavioral changes.4,5 Respira-
tory symptoms associated with GERD mainly include
cough, dyspnea and wheezing.23 Association of
GERD and respiratory symptoms, especially asthma,
is complex and multifactorial. Asthma includes
variable airflow obstruction that changes over a
short period of time associated with demonstration
of respiratory mucosal eosinophilic inflammation in
diagnosis. Therefore, the clinical picture of chronic
recurrent cough, recurrent lower respiratory pro-
blems, wheezing, rhonchi and prolonged expiration
time responsive to bronchodilator administration
was defined as asthma-like airway disease in this
study.26
Smaller group of asthmatic children have been
reported to be nonatopic. There is evidence that
some differences in airway inflammatory mechan-
isms exist between atopic and nonatopic asthmatic
children. Exposure to environmental allergens is
not the major contributing factor in appearance of
symptoms in nonatopic asthmatics. These children
experience exacerbations of disease more com-
monly in response to viral infections, environmen-
tal irritants and endogenous risk factors such as
GER, etc. and nonatopic asthma seems to have a
better prognosis.3,26 It is reported that frequency
of GERD in asthmatic children ranges between
59–75%.10,11,27 However, considering that over 90%
of childhood asthma is atopic in whom exacerba-
tions are provoked by allergen exposure, this
frequency might be higher in the small group with
ARTICLE IN PRESS
Gastroesophageal reflux disease in nonatopic asthma 397nonatopic asthma which does not have a risk factor
as obvious as allergen sensitization.3
In this study, frequency of GERD was 76% in our
group of asthmatic nonatopic children who have no
other provocative factor for airway hyperreactivity.
GERD was defined as total distal RI44 in distal
esophagus determined by the most suitable diag-
nostic tool for GERD, that is the 24 h pH monitoring
with a sensitivity and specificity above 90%.5,7,8
This was significantly higher than that in the control
group (48%, P ¼ 0:04). This is an expected phenom-
enon when the results of previous studies indicating
the coexistence of asthma and GERD are consid-
ered. Therefore, GER may be one of the contribut-
ing factors to exacerbations in nonatopic asthma.
The diagnosis of GER depended on the results of
24 h pH monitoring, therefore nonacid reflux could
not be determined; however, the most sensitive
and specific diagnostic modality for GER is still pH
monitoring and previous literature had also focused
on the effects of acid reflux. Moreover, treatment
with PPIs would not lead to improvement of
symptoms associated with non-acid reflux, there-
fore it was not taken into consideration of this
study.
Despite determination of this association, most
of the time, it cannot be determined if asthma-like
findings are consequences of GERD or vice versa.
Vagal reflex mechanism which increases airway
resistance in response to the increase in esophageal
acidity, neural enhancement of bronchial reactivity
and microaspirations leading to epithelial damage
are accused in the pathophysiology of esophageal
acid induced bronchoconstriction.4,5,17,28,29
Higher frequency of GERD in nonatopic patients
with asthma-like airway disease with recurrent
exacerbations despite adequate anti-asthmatic
treatment suggests the role of this pathology in
the development of bronchoconstriction. However,
some authors have proposed that this phenomenon
depends on the high frequency of respiratory
symptoms and reflux by themselves.30 To avoid
misleading results, not only frequency of GERD but
also response of asthma severity to anti-reflux
treatment was evaluated in this study. In our
patient group, significant reduction in respiratory
symptoms, bronchodilator and steroid require-
ment, number of asthmatic attacks and need for
hospitalization after acid supressor treatment
contributes to the theory that GERD induces
bronchoconstriction. A control group that did not
receive treatment was not included in this study
due to ethical concerns. Therefore, placebo effect
should be considered due to lack of the control
group and due to the waxing and waning clinical
progress of asthma. However, the expected im-provement in asthma symptoms in a placebo group
in clinical trials has been reported to be lower than
30% in childhood. Thus, the significant improve-
ment in our study cannot be attributed to the
placebo effect.31
Similar results were obtained in a previous study
which reported a significant reduction in the
requirement of anti-asthmatic medications in chil-
dren with persistent symptoms.27 This is also
supported by the reduction of chronic symptoms
and requirement of anti-asthmatic treatment after
effective control of GER in another study.32 How-
ever, there is still debate about the issue and there
is literature denying an improvement in lung
function and asthma symptoms with anti-reflux
treatment.30 Results of our study indicate that
sufficient control of GERD lead to a significant
decrease in severity of asthma-like airway disease
in nonatopic patients. Opposite results reported by
some previous studies may be attributed to
inefficient control of GERD as well as other
pathological conditions lying under the respiratory
symptoms in patients.33,34 Moreover, time of the
year during which pre- and post-treatment severity
of disease was evaluated may lead to a bias if not
standardized. In this study, pre-treatment severity
was assessed according to the patient records of
the previous year during the same months as post-
treatment to avoid seasonal variation caused by air
pollution, crowding and increased frequency of
viral infections.
Moreover, distribution of symptoms among our
patients emphasizes an important point in that,
gastrointestinal complaints may be absent in
these nonatopic patients with an asthma-like
respiratory disease. Vomiting which was present
in 4% of the patients was the only gastrointes-
tinal complaint reported. This, as reported by
previous studies necessitates a high index of
suspicion for GERD in nonatopic patients with an
asthma-like airway disease even in the absence
of gastrointestinal symptoms.8 Therefore, asthma-
like respiratory disease as the only presentation
of GERD makes this pathology a topic of pedia-
tric respiratory diseases along with gastroentero-
logy.
In conclusion, GERD is an important factor in
development of asthma-like respiratory disease in
nonatopic children and should be suspected espe-
cially in patients with exacerbations of asthma
despite adequate conventional asthma treatment
because relief of this disorder contributes signifi-
cantly to the control of the respiratory symptoms.
Thus, we suggest that in this subgroup of patients
with asthma-like respiratory disease lansoprazole
may be tried initially.
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